UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 380

Sortiert nach

Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome

Journal of viral hepatitis, 2013-04, Vol.20 (4), p.e72-e77

2013

Volltextzugriff (PDF)

P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING

Journal of hepatology, 2014-04, Vol.60 (1), p.S465-S466

2014

Volltextzugriff (PDF)

P730 ADVERSE EVENTS AND CO-MEDICATION: A COMPARISON BETWEEN DUAL- AND TRIPLE-COMBINATION THERAPIES IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C

Journal of hepatology, 2014-04, Vol.60 (1), p.S313-S313

2014

Volltextzugriff (PDF)

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

Journal of viral hepatitis, 2010-07, Vol.17 (7), p.459-468

2010

Volltextzugriff (PDF)

P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS?

Journal of hepatology, 2014-04, Vol.60 (1), p.S460-S461

2014

Volltextzugriff (PDF)

P1148 BASELINE FACTORS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN

Journal of hepatology, 2014-04, Vol.60 (1), p.S465-S465

2014

Volltextzugriff (PDF)

872 SUBSTANTIAL RENAL IMPAIRMENT IS NOT INFREQUENT IN HCV PATIENTS UNDER TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR

Journal of hepatology, 2013-04, Vol.58, p.S358-S358

2013

Volltextzugriff (PDF)

P1150 BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING

Journal of hepatology, 2014-04, Vol.60 (1), p.S466-S466

2014

Volltextzugriff (PDF)

871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

Journal of hepatology, 2013-04, Vol.58, p.S357-S358

2013

Volltextzugriff (PDF)

875 REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

Journal of hepatology, 2013-04, Vol.58, p.S359-S360

2013

Volltextzugriff (PDF)

Capsule endoscopy for the diagnosis of small bowel diseases. An updated statement by the endoscopy section of DGVS

Zeitschrift fur Gastroenterologie, 2010-12, Vol.48 (12), p.1384

2010

Volltextzugriff (PDF)

1139 VIRAL RESPONSE AT WEEK 2 AS A PREDICITIVE FACTOR FOR RVR IN CHRONIC HCV GENOTYPE 1 INFECTION TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV)

Journal of hepatology, 2012-04, Vol.56, p.S450-S450

2012

Volltextzugriff (PDF)

1149 PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING

Journal of hepatology, 2012-04, Vol.56, p.S454-S454

2012

Volltextzugriff (PDF)

Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)

Zeitschrift fur Gastroenterologie, 2024-04, Vol.62 (4), p.517

2024

Volltextzugriff (PDF)

454 PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S185-S185

2011

Volltextzugriff (PDF)

447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV)

Journal of hepatology, 2011-03, Vol.54, p.S182-S182

2011

Volltextzugriff (PDF)

651 ROLE OF RVR AND VIRAL LOAD ON SVR IN TREATMENT OF GT3 HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE

Journal of hepatology, 2009, Vol.50, p.S239-S240

2009

Volltextzugriff (PDF)

840 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY

Journal of hepatology, 2008, Vol.48, p.S315-S315

2008

Volltextzugriff (PDF)

842 EFFICACY AND TOLERABILITY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN GENOTYPE 4 PATIENTS WITH CHRONIC HEPATITIS C (CHC) UNDER REAL LIFE CONDITIONS

Journal of hepatology, 2008, Vol.48, p.S316-S316

2008

Volltextzugriff (PDF)

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Zeitschrift fur Gastroenterologie, 2020-10, Vol.58 (10), p.982

2020

Volltextzugriff (PDF)

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Zeitschrift fur Gastroenterologie, 2020-07, Vol.58 (7), p.672

2020

Volltextzugriff (PDF)

Prospective multicenter trial of capsule endoscopy in patients with chronic abdominal pain, diarrhea and other signs and symptoms (CEDAP-Plus Study)

Endoscopy, 2007-07, Vol.39 (7), p.606-612

2007

Volltextzugriff (PDF)

Zweitmalignome nach Therapie des Morbus Hodgkin : das Freiburger Kollektiv 1940 bis 1991

Strahlentherapie und Onkologie, 1999-10, Vol.175 (4), p.154-161

1999

Volltextzugriff (PDF)

622 Efficacy and safety of peginterferon alpha-2a (40KD) [PEG] plus ribavirin [RBV] 1000/1200 mg/d in genotype 1 patients with chronic hepatitis C and ‘normal’ ALT levels

Journal of hepatology, 2006-04, Vol.44, p.S231-S231

2006

Volltextzugriff (PDF)

Organic Cotton: Fibre to Fashion

Sustainable Approaches in Textiles and Fashion, 2022, p.275-306

2022

Volltextzugriff (PDF)

1 – 25 von 380

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(291)
Mit Volltextzugriff
(338)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome

P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING

P730 ADVERSE EVENTS AND CO-MEDICATION: A COMPARISON BETWEEN DUAL- AND TRIPLE-COMBINATION THERAPIES IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS?

P1148 BASELINE FACTORS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN

872 SUBSTANTIAL RENAL IMPAIRMENT IS NOT INFREQUENT IN HCV PATIENTS UNDER TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR

P1150 BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING

871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

875 REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

Capsule endoscopy for the diagnosis of small bowel diseases. An updated statement by the endoscopy section of DGVS

1139 VIRAL RESPONSE AT WEEK 2 AS A PREDICITIVE FACTOR FOR RVR IN CHRONIC HCV GENOTYPE 1 INFECTION TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV)

1149 PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING

Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)

454 PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN

447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV)

651 ROLE OF RVR AND VIRAL LOAD ON SVR IN TREATMENT OF GT3 HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE

840 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY

842 EFFICACY AND TOLERABILITY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN GENOTYPE 4 PATIENTS WITH CHRONIC HEPATITIS C (CHC) UNDER REAL LIFE CONDITIONS

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers

Prospective multicenter trial of capsule endoscopy in patients with chronic abdominal pain, diarrhea and other signs and symptoms (CEDAP-Plus Study)

Zweitmalignome nach Therapie des Morbus Hodgkin : das Freiburger Kollektiv 1940 bis 1991

622 Efficacy and safety of peginterferon alpha-2a (40KD) [PEG] plus ribavirin [RBV] 1000/1200 mg/d in genotype 1 patients with chronic hepatitis C and ‘normal’ ALT levels

Organic Cotton: Fibre to Fashion

Suchergebnisse filtern